11.66

1.92% 0.22

After Hours: 11.58 -0.08 -0.69%

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $11.66, with a volume of 4.85M. It is up +1.92% in the last 24 hours and up +11.47% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Previous Close:

$11.44

Open:

$11.35

24h Volume:

4.85M

Relative Volume:

0.85

Market Cap:

$3.54B

Revenue:

Net Income/Loss:

$-449.64M

P/E Ratio:

-5.2054

EPS:

-2.24

Net Cash Flow:

$-405.08M

1W Performance:

+7.86%

1M Performance:

+11.47%

6M Performance:

-14.45%

1Y Performance:

+176.96%

1-Day Range:

$11.03

$11.70

1-Week Range:

$10.38

$11.70

52-Week Range:

$3.76

$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

557

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IOVA's Discussions on Twitter

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

03:49 AM

Iovance Biotherapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga

03:49 AM

Nov 01, 2024

Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024

Oct 31, 2024

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - The Manila Times

Oct 31, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) Now Covered by Analysts at UBS Group - MarketBeat

Oct 24, 2024

Oct 19, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 19, 2024

Oct 18, 2024

Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA) - MarketBeat

Oct 18, 2024

State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc - Yahoo Finance

Oct 18, 2024

First Week of October 18th Options Trading For Iovance Biotherapeutics - Nasdaq

Oct 18, 2024

Oct 17, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7%Should You Buy? - MarketBeat

Oct 17, 2024

Oct 16, 2024

Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts? - Insider Monkey

Oct 16, 2024

Oct 14, 2024

Tumor Infiltrating Lymphocyte (TIL) Market Development Status 2034 |Iovance Biotherapeutics, Optera Therapeutics Corp, T – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024

Oct 12, 2024

Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy? - Insider Monkey

Oct 12, 2024

Oct 11, 2024

Iovance Biotherapeutics (FRA:2LB) Debt-to-EBITDA : -0.22 (As of Jun. 2024) - GuruFocus.com

Oct 11, 2024

Oct 10, 2024

Is Iovance Biotherapeutics, Inc. (IOVA) the Best Stock Under $10 With High Potential? - Yahoo Finance

Oct 10, 2024

Strong Investor Sentiment: Artisan Partners Highlights Iovance Biotherapeutics, Inc. (IOVA) - MSN

Oct 10, 2024

Oct 06, 2024

10 Best Biotech Stocks To Buy Under $20 - Insider Monkey

Oct 06, 2024

Oct 05, 2024

Sei Investments Co. Has $2.28 Million Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Oct 05, 2024

Oct 04, 2024

Is Iovance Biotherapeutics Stock a Buy? - MSN

Oct 04, 2024

Is Iovance Biotherapeutics Stock a Buy? - The Motley Fool

Oct 04, 2024

Squarepoint Ops LLC Purchases Shares of 257,543 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Oct 04, 2024